Literature DB >> 2427531

Biotherapy: the fourth modality of cancer treatment.

R K Oldham.   

Abstract

Biotherapy represents a new modality of cancer treatment. It utilizes biologicals and biological response modifiers in the treatment of cancer. Many of these substances are of "natural" origin emanating from mammalian cells as physiologic mediators of immune response and as substances active in the regulation of growth and maturation. With the advent of molecular biological techniques, hybridoma technology, and computer applications, it is now possible to prepare these biological substances in highly purified form and in large quantities for use as medicinals. The expertise required to apply these biotherapeutic approaches to the treatment of cancer often involves the use of immunological and/or molecular biological capabilities. Because of the rather specialized expertise needed to understand and apply these substances as anticancer approaches, those individuals with expertise in the application of chemotherapy to patients with cancer are not necessarily well prepared for the translation of biotherapy to the clinic. Biotherapeutic approaches are broad and involve a whole range of physiological responses inherent in cancer biology. The approaches necessary to bring these biotherapeutic capabilities to the clinic need to be considered carefully, and the use of new techniques and new methods of application should be encouraged so as not to inhibit these potentially powerful anticancer approaches. As natural mediators, many biologicals have much less inherent toxicity than the drugs previously used in systemic cancer therapy. Therefore, the systems for translating these substances from the laboratory to the clinic should be restructured for the rapid translation of biotherapy to the patient.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2427531     DOI: 10.1002/jcp.1041290416

Source DB:  PubMed          Journal:  J Cell Physiol Suppl        ISSN: 0737-1462


  6 in total

1.  Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.

Authors:  G Gasparini; S Dal Fior; F Pozza; G A Panizzoni; S Favretto; D D Von Hoff
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

2.  Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells.

Authors:  Lin Lu; Huimin Tao; Alfred E Chang; Yangyang Hu; Guoshun Shu; Quanning Chen; Martin Egenti; John Owen; Jeffrey S Moyer; Mark Ep Prince; Shiang Huang; Max S Wicha; Jian-Chuan Xia; Qiao Li
Journal:  Oncoimmunology       Date:  2015-01-09       Impact factor: 8.110

3.  Is there a role for therapeutic cancer vaccines in the age of checkpoint inhibitors?

Authors:  Robert O Dillman
Journal:  Hum Vaccin Immunother       Date:  2016-11-03       Impact factor: 3.452

Review 4.  Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics.

Authors:  Ruipeng Mu; Jiaqi Yuan; Yue Huang; John K Meissen; Si Mou; Meina Liang; Anton I Rosenbaum
Journal:  BioDrugs       Date:  2022-04-01       Impact factor: 7.744

5.  A new strategy using ALDHhigh-CD8+T cells to inhibit tumorigenesis.

Authors:  Huiyan Luo; Changqing Zeng; Cheng Fang; Sharvesh Raj Seeruttun; Lin Lv; Wei Wang
Journal:  PLoS One       Date:  2014-08-08       Impact factor: 3.240

6.  Soluble HLA-associated peptide from PSF1 has a cancer vaccine potency.

Authors:  Mari Yoshida; Yukichi Ishioka; Takamasa Ozawa; Hirohisa Okuyama; Motofumi Iguchi; Takeshi Ota; Takaomi Ito; Morio Nagira; Atsushi Morita; Hidekazu Tanaka; Hisamichi Naito; Hiroyasu Kidoya; Nobuyuki Takakura
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.